Related Experiment Video
Updated: Mar 10, 2026
12:36
A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1
Published on: July 22, 2022
5.1K
Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro
Roxanne Hastie1, Stephen Tong1, Natalie J Hannan1
11 Department of Obstetrics and Gynaecology, Translational Obstetrics Group, Mercy Hospital for Women, University of Melbourne, Melbourne, Victoria, Australia.
Reproductive Sciences (Thousand Oaks, Calif.)
|December 7, 2016
Summary
Epidermal growth factor (EGF) may treat preeclampsia by reducing endothelial dysfunction. This study shows EGF lessens key markers of vascular damage in human cells, offering hope for new therapies.
Area of Science:
- Obstetrics and Gynecology
- Vascular Biology
- Cell Biology
Background:
- Preeclampsia is a serious hypertensive disorder of pregnancy causing significant maternal mortality.
- Endothelial dysfunction is a key pathological feature of preeclampsia.
- Currently, no specific medical treatments exist for preeclampsia-related endothelial dysfunction.
Purpose of the Study:
- To investigate the therapeutic potential of epidermal growth factor (EGF) in mitigating endothelial dysfunction.
- To assess EGF's effects on primary human vascular cells under preeclampsia-mimicking conditions.
Main Methods:
- In vitro assays using primary human umbilical vein endothelial cells (HUVECs).
- Exposure of HUVECs to tumor necrosis factor α (TNF-α) or serum from preeclamptic women.
- Evaluation of vascular cell adhesion molecule-1 (VCAM-1) expression.
- Assessment of monocyte adhesion and tube formation disruption.
Main Results:
- EGF significantly reduced VCAM-1 expression induced by TNF-α or preeclamptic serum.
- EGF inhibited TNF-α-induced monocyte adhesion to HUVECs.
- EGF lessened TNF-α-induced disruption of endothelial tube formation.
Conclusions:
- EGF demonstrates a protective effect against endothelial dysfunction in primary human cells.
- Epidermal growth factor shows promise as a potential novel therapeutic agent for preeclampsia.
- EGF may be beneficial for other conditions characterized by endothelial dysfunction.
